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In recent years, significant changes have occurred in 
the management of respiratory tract infections, largely 
because of the increased resistance of the three main 
respiratory pathogens, Streptococcus pneumoniae, Haemo- 
philus infuenzae and Moraxella catarrhalis, to commonly 
used antibiotics. The increasing problem of resistance 
to p-lactams and macrolides has resulted in the need for 
alternative therapies. Among the new drugs available 
for the treatment of respiratory tract infections, some 
of the newer fluoroquinolones could be a suitable 
option. 
Several significant developments in the field of 
respiratory tract infections occurred in 1976 and 1977 
with the establishment of Legionella as a causative 
pathogen: the identification of P-lactamase-producing 
strains of H .  infuenzae; the identification of penicillin- 
resistant strains of S. prieumoniae in South Africa; the 
discovery of several cephalosporins and the beginning 
of the fluoroquinolones with norfloxacin. 
Initially, fluoroquinolones were not viewed as 
suitable agents for respiratory tract infections because 
of their poor activity against S. pneumoniae. During 
the 1980s, limited clinical experience was gained in 
small studies with several fluoroquinolones, namely 
norfloxacin, enoxacin and pefloxacin, mainly in Japan, 
with cure rates of approximately 70%. Satisfactory 
results were obtained in extended clinical studies of 
ciprofloxacin and ofloxacin but problems of persistence 
of S. pneumoniae, clinical relapse and development of 
resistance were reported which led to a reluctance 
among clinicians to use these compounds as first-line 
treatment in community-acquired pneumonia. In the 
early I990s, however, fluoroquinolones were used for 
the treatment of respiratory tract infections where 
S. pneumoniae infection was excluded. 
A number of new fluoroquinolones, such as 
levofloxacin, trovafloxacin, sparfloxacin, gatifloxacin, 
grepafloxacin and clinafloxacin, are being developed 
with improved activity against Gram-positive patho- 
gens, particularly s. pneumoniae. The purpose of this 
workshop meeting was to discuss the role of these 
newer agents in the treatment of respiratory tract 
infections and to try to reach a consensus about 
whether they constitute a new class of fluoroquinolones 
which are clinically effective in these indications, 
including S. pneumoniae infection. Five workgroups 
discussed these agents under the topics of microbiology, 
resistance, pharmacokinetics and pharmacodynarnics, 
and lower and upper respiratory tract infections. These 
workgroup discussions and presentations form the basis 
of this supplement together with a paper on the 
immunopathology of respiratory tract infections, the 
substance of which was presented during a plenary 
session of the meeting. 
